Immutep (Germany)

Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma

Victoria Atkinson, Adnan Khattak, Andrew Haydon et al. · Journal for ImmunoTherapy of Cancer · 2020 · 108 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial

Heidi J. Gray, Benedict B. Benigno, Jonathan S. Berek et al. · Journal for ImmunoTherapy of Cancer · 2016 · 48 citations · Full text

Medicine, Immunology, Oncology +16

A LAG-3–Specific Agonist Antibody for the Treatment of T Cell–Induced Autoimmune Diseases

Mathieu Angin, Chrystelle Brignone, Frédéric Triebel · The Journal of Immunology · 2020 · 46 citations

Life Sciences, Immunology, Pathobiology +17

A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer

Paul Mitchell, Michael Quinn, Peter Grant et al. · Journal for ImmunoTherapy of Cancer · 2014 · 40 citations · Full text

Life Sciences, Immunology, Oncology +17

A phase II study (TACTI-002) in first-line metastatic non–small cell lung carcinoma investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab: Updated results from a PD-L1 unselected population.

Enriqueta Felip, Margarita Majem, Bernard Doger et al. · Journal of Clinical Oncology · 2022 · 27 citations

Medicine, Oncology, Pharmacology +14